Results 41 to 50 of about 16,181 (154)

Ticagrelor — a legend of modern cardiology

Российский кардиологический журнал
The article presents the evidence on the basis of which the ticagrelor is used in patients with various forms of coronary artery disease, including both acute and chronic.
S. R. Gilyarevsky
doaj   +1 more source

Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background Ticagrelor is a P2Y12 receptor inhibitor with superior clinical efficacy compared with clopidogrel. However, it is associated with reduced efficacy when combined with a high‐dose aspirin.
Sukhdeep S. Basra, Tracy Y. Wang, DaJuanicia N. Simon, Karen Chiswell, Salim S. Virani, Mahboob Alam, Vijay Nambi, Ali E. Denktas, Anita Deswal, Biykem Bozkurt, Christie M. Ballantyne, Eric D. Peterson, Hani Jneid   +12 more
doaj   +1 more source

Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75–100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study

Platelets, 2020
Patients treated with ticagrelor and aspirin usually suffer from bleeding events, especially mild bleeding which is one of the main factors reducing patients’ adherence to ticagrelor.
Jiannan Li, Zhaoxue Sheng, Yu Tan, Chen Liu, Peng Zhou, Jinying Zhou, Runzhen Chen, Yi Chen, Li Song, Hanjun Zhao, Hongbing Yan   +10 more
doaj   +1 more source

Incidence of Periprocedural Myocardial Injury and Infarction After Intravascular Lithotripsy for Calcified Coronary Artery Stenosis

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Intravascular lithotripsy (IVL) has emerged as an effective technique for modifying heavily calcified coronary plaques, facilitating optimal stent expansion while minimizing procedural complications. However, data on periprocedural myocardial injury (PMI) and infarction (PPMI) following IVL remain scarce.
Gwaenaelle Aellen, Dorian Garin, Yannick Faucherre, Serban Puricel, Mario Togni, Stéphane Cook   +5 more
wiley   +1 more source

Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark

The Lancet Regional Health. Europe, 2022
Summary: Background: Ticagrelor was introduced in Denmark in 2011 after randomised data showed its superiority over clopidogrel for patients with acute coronary syndrome (ACS). We assessed the effectiveness and safety of ticagrelor implementation in ACS
Pernille Gro Thrane, Kevin Kris Warnakula Olesen, Morten Würtz, Christine Gyldenkerne, Morten Madsen, Lisette Okkels Jensen, Bent Raungaard, Henrik Toft Sørensen, Troels Thim, Steen Dalby Kristensen, Michael Maeng   +10 more
doaj   +1 more source

Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross‐sectional study

Clinical Pharmacology &Therapeutics, EarlyView.
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang, Guiling Zhou, Jens H. J. Bos, Eelko Hak, Talitha Feenstra, Frank Klont   +5 more
wiley   +1 more source

Ticagrelor Loading on ST-Elevation Myocardial Infarction: Interaction With Prodromal Angina on Infarct Size and Clinical Events

Journal of Cardiovascular Pharmacology and Therapeutics, 2023
Introduction: Ticagrelor might reduce infarct size by exerting a more potent antiplatelet effect or by promoting a potential conditioning stimulus in ST-elevation myocardial infarction (STEMI) patients.
João Pedro Faria MD, Pedro Oliveira PhD, André Alexandre MD, David Sá Couto MD, Ricardo Costa MD, Andreia Campinas MD, André Frias MD, Bruno Brochado MD, Raquel Santos MD, João Silveira MD, Severo Torres MD, André Luz MD, PhD, FESC   +11 more
doaj   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis

BMC Cardiovascular Disorders, 2018
Background & Aims Ticagrelor has been acknowledged as a new oral antagonist of P2Y12-adenosine diphosphate receptor, as a strategy with more rapid onset as well as more significant platelet inhibition function in acute coronary syndrome (ACS) patients ...
Dong Wang, Xiao-Hong Yang, Ji-Dong Zhang, Rui-Bin Li, Min Jia, Xiao-Ran Cui   +5 more
doaj   +1 more source

Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention

Platelets, 2022
It remains unclear whether low-dose ticagrelor offers better safety and similar efficacy for Asian patients with acute coronary syndromes (ACS). We aimed to compare the safety and effectiveness of low-dose ticagrelor vs standard-dose ticagrelor in ...
Yue Wang, Beibei Liu, Leilei Chen, Yue Wang, Zhiqiang Wang, Xiaojiang Zhang, Min Suo, Gary S. Mintz, Xiaofan Wu   +8 more
doaj   +1 more source